AOD9604

AOD9604 (Anti-Obesity Drug 9604) is a modified synthetic fragment of human growth hormone corresponding to amino acids 177–191, with a tyrosine residue added at the N-terminus (Tyr-hGH177-191). It was specifically engineered to preserve the lipolytic activity of the HGH C-terminal region while eliminating the growth-promoting, IGF-1-stimulating, and insulin resistance-inducing effects associated with full-length HGH.

AOD9604 activates the beta-3 adrenergic receptor (β3-AR) on adipocytes to stimulate intracellular lipolysis via cAMP elevation, without stimulating IGF-1 production or inducing hyperglycemia. It has received GRAS (Generally Recognized As Safe) status from the FDA for food and supplement applications and was evaluated in multiple clinical trials for obesity treatment, providing a strong human safety data foundation for research use.

• Beta-3 adrenergic receptor (β3-AR) activation and cAMP-mediated lipolysis
• Selective adipose tissue fat oxidation without IGF-1 stimulation
• HGH C-terminal fragment pharmacology and receptor specificity
• Obesity, body composition, and adiposity research models
• Insulin sensitivity preservation studies vs full-length HGH
• cAMP-mediated metabolic signaling in adipocytes

Dose levels referenced by the MVLabs peptide calculator, shown for research reference only:

HGH 177-191 fragment. Fasted. No effect on insulin or IGF-1.

Research reference only — not dosing guidance for human use. Use the calculator for other vials or volumes.

Supplied as a lyophilized powder. Store at 2–8 °C on receipt; protect from heat, light and moisture, and avoid excessive agitation. If reconstitution is required for laboratory work, use sterile technique — bacteriostatic water, or 0.6% acetic acid for low-solubility peptides. Protocols vary by research application.